Vitrakvi

Vitrakvi (larotrectinib) is an oral therapy used for treating solid tumors with NTRK gene fusions. This targeted treatment works by blocking specific cancer-causing proteins. Vitrakvi is prescribed for adults and children with advanced or metastatic cancers.

Larotrectinib, sold as Vitrakvi, is a prescription medicine used to treat solid tumors that have a specific genetic feature called an NTRK gene fusion. It is approved for both adult and pediatric patients with advanced or metastatic cancers. This targeted therapy helps slow or stop tumor growth by interfering with proteins that drive cancer progression.

As a targeted oral therapy, larotrectinib works within the body to inhibit proteins that contribute to tumor growth. Patients may experience stabilization of disease or tumor shrinkage over time. Individual responses vary based on tumor type, genetic profile, and overall health.

Larotrectinib should be taken exactly as prescribed by a healthcare provider. Patients should inform their doctor about all medications, supplements, and medical conditions before starting treatment. Regular monitoring may be required to assess response and manage potential side effects.

Certain medications, including strong CYP3A inhibitors or inducers, may affect how larotrectinib works. Grapefruit and grapefruit juice can interact with this medication. Patients should avoid alcohol unless approved by their doctor. Always consult a healthcare professional before combining larotrectinib with other substances.